COVID-19 trials registries data warehouse

 Return to trial list

Trial - NCT05305560


Column Value
Trial registration number NCT05305560
Full text link
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

First author
Last imported at : Jan. 8, 2023, midnight
Source : ClinicalTrials.gov

Not reported

Contact
Last imported at : Jan. 8, 2023, midnight
Source : ClinicalTrials.gov

Not reported

Registration date
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

2022-03-31

Recruitment status
Last imported at : Jan. 8, 2023, midnight
Source : ClinicalTrials.gov

Completed

Study design
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

RCT

Allocation
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Randomized

Design
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Parallel

Masking
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Blind label

Center
Last imported at : March 15, 2023, 4 a.m.
Source : ClinicalTrials.gov

single-center

Study aim
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Prevention

Inclusion criteria
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

inclusion criteria: age between 18 and 65 years, inclusive. body weight >45 kg. body mass index >18.5. close contact with a person who has a pcr-confirmed sars-cov-2 infection within 5 days before screening. only one member in the same household will be enrolled. participants must be able to give informed consent and comply with the study's scheduled events/visits and study assessments. sars-cov-2 positive index case must be able to give consent to enable collection of the documented positive pcr test. female participants of childbearing potential must use a highly effective method of contraception for the duration of the trial.

Exclusion criteria
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

pregnant or breast-feeding. participants who have been administered covid-19 vaccine prior to the inclusion or have a planned vaccination during the duration of the study. a positive covid-19 result (pcr or antigen test) within 8 days of screening. presence of typical covid-19 symptoms (fever >38°c, spo2 below 93%, dyspnoea, difficulty breathing, chills, repeated shaking with chills, ageusia, anosmia, cough, myalgia, headache) in the past 48 hours prior to screening. hypersensitivity to any component of ivermectin. participants who have been administered ivermectin within 30 days prior to screening. participation in another interventional trial within the last 30 days or 5 half-lives of the imp of the other trial, whichever comes first. participants with gastrointestinal erosions and ulcers (e.g. erosive esophagitis, stomach ulcers, ulcerative colitis etc.). history of neurotoxicity with ivermectin or other para-glycoprotein (p-gp) substrates or inhibitors. current use of monoclonal antibodies for the treatment of covid-19.

Number of arms
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

2

Funding
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

MedinCell S.A

Inclusion age min
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

18

Inclusion age max
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

65

Countries
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Bulgaria

Type of patients
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Close contacts to covid patients

Severity scale
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

N/A

Total sample size
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

400

primary outcome
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

COVID-19 prophylaxis

Notes
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

None

Phase
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

Phase 2

Arms
Last imported at : April 1, 2022, 3:30 p.m.
Source : ClinicalTrials.gov

[{"arm_notes": "nan", "treatment_id": 693, "treatment_name": "Ivermectin", "treatment_type": "Antiparasitics", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]